Please assess the completion status of the following clinical trial:

Trial Title: 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 3 to \< 12 months~* Diagnosis of AD fulfilling the diagnostic criteria of Seymour~* AD affecting at least 5% total body surface area~* Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to mild-to-moderate disease at baseline~* Informed consent~Exclusion Criteria:~* Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks~* Topical tacrolimus or pimecrolimus within 2 weeks~* Topical therapy (e.g., tar, topical corticosteroids) within 3 days~* Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease~* Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected AD~* Failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile~* Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids~* Clinical conditions other than AD that according to investigator can interfere with the evaluation

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Pimecrolimus
- 2 (Type: ACTIVE_COMPARATOR): Topical corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).